idarubicin has been researched along with paclitaxel in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 10 (55.56) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Heijn, M; Hooijberg, JH; Lankelma, J; Scheffer, GL; Szabó, G; Westerhoff, HV | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Baguley, BC; Davey, MW; Davey, RA; Hargrave, RM; Harvie, RM; Su, GM | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
| Bassan, R; Di Gaetano, N; Erba, E; Golay, J; Introna, M; Rambaldi, A; Xiao, Y | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Beck, JF; Bien, S; Gratz, M; Kroemer, HK; Ritter, CA; Sonnemann, J; Sperker, B | 1 |
| Chignola, R; Dalla Pellegrina, C; Tomelleri, C | 1 |
| Boulinguez, S; Gadaud, N; Gladieff, L; Guenounou, S; Lamant, L; Masson Regnault, M; Recher, C; Roche, H; Sibaud, V; Tournier, E | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
3 review(s) available for idarubicin and paclitaxel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Eruptions; Female; Humans; Hyperpigmentation; Idarubicin; Lomustine; Male; Middle Aged; Paclitaxel; Vincristine | 2015 |
1 trial(s) available for idarubicin and paclitaxel
| Article | Year |
|---|---|
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |
14 other study(ies) available for idarubicin and paclitaxel
| Article | Year |
|---|---|
Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport.
Topics: Adenosine Triphosphate; Anthracyclines; ATP-Binding Cassette Transporters; Binding Sites; Biological Transport; Cell Membrane; Daunorubicin; Glutathione; Humans; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 1997 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro.
Topics: Acridines; Amsacrine; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buthionine Sulfoximine; Cell Line; Cell Survival; Daunorubicin; Drug Resistance, Multiple; HL-60 Cells; Humans; Idarubicin; Leukemia; Paclitaxel; Phenotype; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured; Verapamil | 1997 |
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Northern; Cisplatin; Complement System Proteins; Cytotoxicity Tests, Immunologic; Doxorubicin; Drug Synergism; Fluorescent Antibody Technique; Humans; Idarubicin; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Paclitaxel; Rituximab; Tumor Cells, Cultured; Vidarabine | 2001 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
Nuclear factor-kappaB mediates up-regulation of cathepsin B by doxorubicin in tumor cells.
Topics: Anthracyclines; Camptothecin; Cathepsin B; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Female; Fluorescent Antibody Technique; Gene Expression; HeLa Cells; Humans; I-kappa B Proteins; Idarubicin; NF-kappa B; NF-kappa B p50 Subunit; NF-KappaB Inhibitor alpha; Paclitaxel; RNA, Messenger; Time Factors; Tumor Cells, Cultured; Up-Regulation | 2004 |
Microplate spectrophotometry for high-throughput screening of cytotoxic molecules.
Topics: Animals; B-Lymphocytes; Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Colchicine; Culture Media; Cytotoxins; Epithelial Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Idarubicin; Kinetics; Leukemia, Biphenotypic, Acute; Paclitaxel; Sensitivity and Specificity; Spectrophotometry; T-Lymphocytes; Time Factors | 2010 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |